Intuitive Surgical Slumps 3.76% on $1.16 Billion Volume Surge as It Ranks 82nd in U.S. Trading Activity

On September 10, 2025, , . . equity market, reflecting heightened investor engagement amid mixed market sentiment.

Recent developments indicate shifting dynamics in the medical technology sector. A pending FDA review of a next-generation robotic platform has introduced regulatory uncertainty, dampening short-term investor confidence. Analysts noted that while the company maintains a dominant market position, near-term earnings guidance remains cautious due to supply chain constraints affecting device installations. Institutional outflows observed in after-hours trading further underscored profit-taking pressures.

Strategic positioning for the back-test period (2022-01-03 to 2025-09-10) assumes equal-weighted exposure to 500 actively traded U.S. stocks, excluding ETFs and preferred shares. Positions are entered at daily close prices with a one-day holding period. Transaction costs are excluded from the calculation. The resulting portfolio return series will be derived from daily volume and closing price data across the specified timeframe.